Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
1 2 3 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Delta 4–OTHER: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office 2021-04-07
Delta 4–SEVERAL: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office 2021-04-07
Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA 2021-04-01
Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience 2021-03-30
Cytosurge–Univ Tübingen: genome editing, 202103 collab cell line developm using FluidFM nano-injection for single cell CRISPR gene engineering 2021-03-24
Formycon–Leukocare: biopharmaceuticals, 202103– collab Master Service Agreem developm stable formulations for biosimilars/biologics of Formycon 2021-03-24
Indivumed–Live Wire Strategic Communications: public relations, 202103 service existent by Live Wire 2021-03-18
Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare 2021-03-17
GenMark–Roche: investment, 202103– acquisition $1.8b recommended cash tender offer at $24.05/share premium of 43% 2021-03-15
Monte Rosa Therapeutics–Aisling Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Aisling Capital 2021-03-12
Monte Rosa Therapeutics–Alphabet: investment, 202103 financing round Series C totalling $95m incl existing + co-investor GV 2021-03-12
Monte Rosa Therapeutics–Amzak Health: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Amzak Health 2021-03-12
Monte Rosa Therapeutics–Avoro Capital: investment, 202103 financing round Series C totalling $95m incl new + lead investor Avoro Capital Advisors 2021-03-12
Monte Rosa Therapeutics–BlackRock: investment, 202103 financing round Series C totalling $95m incl new + co-investor BlackRock 2021-03-12
Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202103 financing round Series C totalling $95m incl existing + co-investor CAM 2021-03-12
Monte Rosa Therapeutics–Casdin Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Casdin Capital 2021-03-12
Monte Rosa Therapeutics–Cormorant Asset Management: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Cormorant 2021-03-12
Monte Rosa Therapeutics–Fidelity: investment, 202103 financing round Series C totalling $95m incl new + co-investor Fidelity Management & Research Co 2021-03-12
Monte Rosa Therapeutics–HBM: investment, 202103 financing round Series C totalling $95m incl existing + co-investor HBM Healthcare Investments 2021-03-12
Monte Rosa Therapeutics–New Enterprise Associates: investment, 202103 financing round Series C totalling $95m incl existing + co-investor NEA 2021-03-12
Monte Rosa Therapeutics–RTW Investments: investment, 202103 financing round Series C totalling $95m incl new + co-investor RTW Investments 2021-03-12
Monte Rosa Therapeutics–SEVERAL: investment, 202103 financing round Series C $95m led by new investor Avoro Capital Advisors 2021-03-12
Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Sixty Degree 2021-03-12
Monte Rosa Therapeutics–T Rowe Price: investment, 202103 financing round Series C totalling $95m incl new + co-investor T Rowe Price Associates Inc 2021-03-12
Monte Rosa Therapeutics–Versant Ventures: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Versant Ventures 2021-03-12
Relief Therapeutics–OTHER: investment, 202103 private placement CHF10m with 41.5m shares at CHF0.2412/share with institutional US investor 2021-03-12
AgomAb Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF 2021-03-10
AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group 2021-03-10
AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications 2021-03-10
BellaSeno–Akampion: public relations, 202103 service existent by Akampion 2021-03-10
BellaSeno–Fraunhofer: implant production technology, 202103– collab developm automated resorbable implant production + QC with Fraunhofer IPT 2021-03-10
BellaSeno–Germany (govt): grant, 202103– KUM-innovativ grant totalling €1.4m tog with Fraunhofer IPT from BMBF 2021-03-10
BioPhero–Novo Group: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Novo Holdings 2021-03-09
BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings 2021-03-09
BioPhero–Syngenta: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Syngenta Ventures 2021-03-09
Lophius–Mikrogen: investment, 202103 acquisition of assets + technologies incl takeover of entire team + lab in Regensburg by Mikrogen 2021-03-08
Exscientia–BlackRock: investment, 202103 financing round Series C extension totalling $40m + closing at total of $100m incl new investor BlockRock 2021-03-04
Exscientia–SEVERAL: investment, 202103 financing round Series C extension $40m + closing at total of $100m with BlockRock joining existing investors 2021-03-04
Atai Life Sciences–KCSA Strategic Communications: public relations, 202103 service existent KCSA is media contact 2021-03-03
Atai Life Sciences–SEVERAL: investment, 202103 financing round Series D $157m co-led by Apeiron + Thiel Capital 2021-03-03
ActiTrexx–SEVERAL: investment, 202103 financing round Series A €3.5m led by LBBW Venture Capital GmbH 2021-03-02
Kairos GmbH–Iqvia: investment, 202103 acquisition of Kairos GmbH by Iqvia 2021-03-01
Silicon Therapeutics–Roivant: investment, 202102– acquisition $450m in shares + milestones by Roivant Sciences ANNOUNCED 2021-02-26
Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc 2021-02-24
Vividion Therapeutics–SEVERAL: investment, 202102 financing round Series C $135m co-led by new investors Logos Capital + Boxer Capital 2021-02-24
Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares 2021-02-15
Sophia Genetics–Gilmartin Group: public relations, 202102 service existent Gilmartin Group is investor contact 2021-02-11
InfanDx–Akampion: public relations, 202102 service existent by Akampion 2021-02-04
Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets 2021-02-04
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund 2021-02-03
Genopis–Wacker: investment, 202102 acquisition of Genopis Inc for $39m in cash + milestones from Helixmith Co Ltd + Medivate Partners LLC 2021-02-03
Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy 2021-02-02
Avacta–Adeptrix: MS-based SARS-CoV-2 test, 202101 collab existent developm of BAMS SARS-CoV-2 assay for research + IVD 2021-01-28
Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test 2021-01-28
Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund 2021-01-28
GeneQuine–Brandenburg (govt): grant, 202101 grant €900k from investment bank of federal state Brandenburg 2021-01-26
GeneQuine–High-Tech Gründerfonds: investment, 202101 financing round Series A totalling €5.4m incl existing + co-investor HTGF 2021-01-26
GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA 2021-01-26
GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences 2021-01-26
GeneQuine–Samum: credit, 202101 convertible loans totalling €2.75m from Pacira BioSciences Inc + Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–Samum: investment, 202101 financing round Series A totalling €5.4m incl co-investor Samum Vermögensverwaltungs GmbH 2021-01-26
GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences 2021-01-26
Microcaps–SEVERAL: investment, 202101 seed financing round CHF5m co-led by Helvetica Capital + ZKB 2021-01-26
Cellvie–Forever Healthy: investment, 202101 seed financing round totalling $5m incl lead investor Kizoo Technology Capital 2021-01-25
Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital 2021-01-25
CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share 2021-01-25
i3 Membrane–High-Tech Gründerfonds: investment, 202101 financing round totalling 7-figure € sum inkl existing investor HTGF 2021-01-25
i3 Membrane–OTHER: investment, 202101 financing round totalling 7-figure € sum incl three private investors 2021-01-25
i3 Membrane–SEVERAL: investment, 202101 financing round 7-figure € sum from HTGF + three private investors 2021-01-25
TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund 2021-01-25
TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital 2021-01-25
Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx 2021-01-21
AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones 2021-01-20
Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.5m at Nasdaq 2021-01-20
Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services 2021-01-20
LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH 2021-01-18
LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF 2021-01-18
LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG 2021-01-18
LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG 2021-01-18
IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments 2021-01-13
IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments 2021-01-13
Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors 2021-01-13
Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share 2021-01-12
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based 2021-01-11
Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI 2021-01-11
Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED 2021-01-11
Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag 2021-01-11
Labforward–Peppermint: investment, 202101 financing round Series B totalling >€5m incl existing + co-investor Peppermint VenturePartners 2021-01-11
Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners 2021-01-11
Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake 2021-01-11
Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP 2021-01-11
Valo Health–Canada (govt): investment, 202101 financing round Series B totalling $190m incl lead investor PSP Investments 2021-01-11
Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments 2021-01-11
Valo Health–SEVERAL: investment, 202101 financing round Series B $190m led by PSP Investments 2021-01-11
Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies 2021-01-08
AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck 2021-01-07
BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund 2021-01-07
BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
1 2 3 ... 29 30 31  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] No Content Marketing 650x80px

» top